Investigational Drug Information for SHR4640
✉ Email this page to a colleague
What is the development status for investigational drug SHR4640?
SHR4640 is an investigational drug.
There have been 18 clinical trials for SHR4640.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 30th 2019.
The most common disease conditions in clinical trials are Hyperuricemia, Gout, and Arthritis, Gouty. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Atridia Pty Ltd., and [disabled in preview].
There is one US patent protecting this investigational drug and thirty-five international patents.
Summary for SHR4640
| US Patents | 1 |
| International Patents | 35 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 2 (2019-07-30) |
| Vendors | 21 |
Recent Clinical Trials for SHR4640
| Title | Sponsor | Phase |
|---|---|---|
| PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
Clinical Trial Summary for SHR4640
Top disease conditions for SHR4640
Top clinical trial sponsors for SHR4640
US Patents for SHR4640
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SHR4640 | ⤷ Sign Up | Quinoline compounds, preparation methods thereof, and uses thereof as urate transporter inhibitor drug | HINOVA PHARMACEUTICALS INC. (Chengdu, Sichuan, CN) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
